For research use only. Not for therapeutic Use.
BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation[1].
| CAS Number | 305339-41-7 |
| Synonyms | 4-(trifluoromethoxy)-N’-[[2-(trifluoromethyl)phenyl]methyl]benzenecarboximidamide |
| Molecular Formula | C16H12F6N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C16H12F6N2O/c17-15(18,19)13-4-2-1-3-11(13)9-24-14(23)10-5-7-12(8-6-10)25-16(20,21)22/h1-8H,9H2,(H2,23,24) |
| InChIKey | YGOCAMFQDLFNQK-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)CN=C(C2=CC=C(C=C2)OC(F)(F)F)N)C(F)(F)F |
| Reference | [1]. Truong L, et, al. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. Brain Res Bull. 2009 Feb 16;78(2-3):91-6. |
